





Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China

Wen-hua Liang^{1,25}, Wei-jie Guan^{1,25}, Cai-chen Li^{1,25}, Yi-min Li^{2,25}, Heng-rui Liang^{1,25}, Yi Zhao^{1,25}, Xiao-qing Liu², Ling Sang^{2,3}, Ru-chong Chen⁴, Chun-li Tang⁴, Tao Wang⁴, Wei Wang¹, Qi-hua He¹, Zi-sheng Chen¹, Sook-San Wong¹, Mark Zanin⁵, Jun Liu¹, Xin Xu¹, Jun Huang¹, Jian-fu Li¹, Li-min Ou¹, Bo Cheng¹, Shan Xiong¹, Zhan-hong Xie⁴, Zheng-yi Ni³, Yu Hu⁶, Lei Liu^{7,8}, Hong Shan⁹, Chun-liang Lei¹⁰, Yi-xiang Peng¹¹, Li Wei¹², Yong Liu¹³, Ya-hua Hu¹⁴, Peng Peng¹⁵, Jian-ming Wang¹⁶, Ji-yang Liu¹⁷, Zhong Chen¹⁸, Gang Li¹⁹, Zhi-jian Zheng²⁰, Shao-qin Qiu²¹, Jie Luo²², Chang-jiang Ye²³, Shao-yong Zhu²⁴, Lin-ling Cheng⁴, Feng Ye⁴, Shi-yue Li^{4,10}, Jin-ping Zheng⁴, Nuo-fu Zhang^{4,6}, Nan-shan Zhong^{1,26} and Jian-xing He^{1,26}

Affiliations: ¹China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. ²Dept of Pulmonary and Critical Care Medicine, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. ³Wuhan Jin-yin tan Hospital, Wuhan, China. ⁴Dept of Respiratory Disease, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. ⁵School of Public Health, The University of Hong Kong, Hong Kong SAR, China. ⁵Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ⁵Shenzhen Third People's Hospital, Shenzhen, China. ³The Second Affiliated Hospital of Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China. ⁵The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China. ¹0Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China. ¹1The Central Hospital of Wuhan, Wuhan, China. ¹2Wuhan No. 1 Hospital, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, China. ¹13Chengdu Public Health Clinical Medical Center, Chengdu, China. ¹4Huangshi, Central Hospital of Edong Healthcare Group, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China. ¹5Wuhan Pulmonary Hospital, Wuhan, China. ¹6Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China. ¹7The First Hospital of Changsha, Changsha, China. ¹8The Third People's Hospital of Hubei University of Medicine, Shiyan, China. ²3Xiantao First People's Hospital of Hubei University of Medicine, Shiyan, China. ²5These authors are joint first authors. ²6Both authors are joint principal authors.

Correspondence: Jian-xing He, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou, China. E-mail: drjianxing.he@gmail.com

@ERSpublications

This study highlights the necessity of urgent and vigorous support of healthcare resources and increased public awareness during the early stages of an outbreak of COVID-19 or similar diseases https://bit.ly/39OWFf0

Cite this article as: Liang W-hua, Guan W-jie, Li C-chen, *et al.* Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. *Eur Respir J* 2020; 55: 2000562 [https://doi.org/10.1183/13993003.00562-2020].

This single-page version can be shared freely online.

ABSTRACT

Background: During the outbreak of coronavirus disease 2019 (COVID-19), consistent and considerable differences in disease severity and mortality rate of patients treated in Hubei province compared to those in other parts of China have been observed. We sought to compare the clinical characteristics and outcomes of

Copyright ©ERS 2020. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

patients being treated inside and outside Hubei province, and explore the factors underlying these differences. **Methods:** Collaborating with the National Health Commission, we established a retrospective cohort to study hospitalised COVID-19 cases in China. Clinical characteristics, the rate of severe events and deaths, and the time to critical illness (invasive ventilation or intensive care unit admission or death) were compared between patients within and outside Hubei. The impact of Wuhan-related exposure (a presumed key factor that drove the severe situation in Hubei, as Wuhan is the epicentre as well the administrative centre of Hubei province) and the duration between symptom onset and admission on prognosis were also determined.

Results: At the data cut-off (31 January 2020), 1590 cases from 575 hospitals in 31 provincial administrative regions were collected (core cohort). The overall rate of severe cases and mortality was 16.0% and 3.2%, respectively. Patients in Hubei (predominantly with Wuhan-related exposure, 597 (92.3%) out of 647) were older (mean age 49.7 versus 44.9 years), had more cases with comorbidity (32.9% versus 19.7%), higher symptomatic burden, abnormal radiologic manifestations and, especially, a longer waiting time between symptom onset and admission (5.7 versus 4.5 days) compared with patients outside Hubei. Patients in Hubei (severe event rate 23.0% versus 11.1%, death rate 7.3% versus 0.3%, HR (95% CI) for critical illness 1.59 (1.05–2.41)) have a poorer prognosis compared with patients outside Hubei after adjusting for age and comorbidity. However, among patients outside Hubei, the duration from symptom onset to hospitalisation (mean 4.4 versus 4.7 days) and prognosis (HR (95%) 0.84 (0.40–1.80)) were similar between patients with or without Wuhan-related exposure. In the overall population, the waiting time, but neither treated in Hubei nor Wuhan-related exposure, remained an independent prognostic factor (HR (95%) 1.05 (1.01–1.08)).

Conclusion: There were more severe cases and poorer outcomes for COVID-19 patients treated in Hubei, which might be attributed to the prolonged duration of symptom onset to hospitalisation in the epicentre. Future studies to determine the reason for delaying hospitalisation are warranted.